CYP2A6 genotype and the metabolism and disposition kinetics of nicotine

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 457-467

  Benowitz, Neal L ^a   Swan, Gary E ^a   Jacob III, Peyton ^a   Lessov Schlaggar, Christina N ^a   Tyndale, Rachel F ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; DEUTERIUM; NICOTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; GENOTYPE; HALF LIFE TIME; HUMAN; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SMOKING; URINARY EXCRETION; WILD TYPE;

ADOLESCENT; ADULT; AGED; ALLELES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; COTININE; DEUTERIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIONIC STIMULANTS; GENE FREQUENCY; GLUCURONIDES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; ISOENZYMES; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NICOTINE; POLYMORPHISM, GENETIC; TIME FACTORS; TWINS;

EID: 33750518486     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.08.011     Document Type: Article

References (34)

1. Xu C., Goodz S., Sellers E.M., and Tyndale R.F. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 54 (2002) 1245-1256
2. Hukkanen J., Jacob III P., and Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57 (2005) 79-115
3. Nakajima M., and Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 20 (2005) 227-235
4. Yamanaka H., Nakajima M., Nishimura K., Yoshida R., Fukami T., Katoh M., et al. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 22 (2004) 419-425
5. Fukami T., Nakajima M., Higashi E., Yamanaka H., McLeod H.L., and Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol 70 (2005) 801-808
6. Dempsey D., Tutka P., Jacob III P., Allen F., Schoedel K., Tyndale R.F., et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76 (2004) 64-72
7. Malaiyandi V., Lerman C., Benowitz N.L., Jepson C., Patterson F., and Tyndale R.F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11 (2006) 400-409
8. Benowitz N.L., Jacob III P., and Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 41 (1987) 467-473
9. Schoedel K.A., Hoffmann E.B., Rao Y., Sellers E.M., and Tyndale R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14 (2004) 615-626
10. Malaiyandi V., Sellers E.M., and Tyndale R.F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77 (2005) 145-158
11. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E.M., et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58 (2000) 747-755
12. Swan G.E., Benowitz N.L., Jacob III P., Lessov C.N., Tyndale R.F., Wilhelmsen K., et al. Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res 7 (2004) 435-448
13. Swan G.E., Benowitz N.L., Lessov C.N., Jacob III P., Tyndale R.F., and Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 15 (2005) 115-125
14. Jacob III P., Benowitz N.L., and Shulgin A.T. Synthesis of optically pure deuterium-labeled nicotine, nornicotine and cotinine. J Labelled Comp Radiopharm 25 (1988) 1117-1128
15. Jacob III P., Yu L., Wilson M., and Benowitz N.L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom 20 (1991) 247-252
16. Mwenifumbo J.C., Myers M.G., Wall T.L., Lin S.K., Sellers E.M., and Tyndale R.F. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 15 (2005) 189-192
17. Jacob III P., Yu L., and Benowitz N.L. Determination of nicotine, its major metabolites, and deuterium-labeled isotopomers in human urine using LC-MS/MS [abstract]. Drug Metab Rev 34 (2002) 160
18. Jacob III P., Shulgin A.T., Yu L., and Benowitz N.L. Determination of the nicotine metabolite trans-3'-hydroxycotinine in urine of smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J Chromatogr 583 (1992) 145-154
19. Benowitz N.L., Jacob III P., Fong I., and Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268 (1994) 296-303
20. Perez-Stable E.J., Herrera B., Jacob III P., and Benowitz N.L. Nicotine metabolism and intake in black and white smokers. JAMA 280 (1998) 152-156
21. Messina E.S., Tyndale R.F., and Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282 (1997) 1608-1614
22. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24 (1996) 1212-1217
23. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277 (1996) 1010-1015
24. Wellek S. Tests for establishing compatibility of an observed genotype distribution with Hardy-Weinberg equilibrium in the case of a biallelic locus. Biometrics 60 (2004) 694-703
25. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29 (2001) 91-95
26. Kiyotani K., Yamazaki H., Fujieda M., Iwano S., Matsumura K., Satarug S., et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 13 (2003) 689-695
27. Oscarson M., McLellan R.A., Asp V., Ledesma M., Bernal Ruiz M.L., Sinues B., et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 20 (2002) 275-283
28. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.T., and Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74 (2003) 69-76
29. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., and Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284 (2001) 455-460
30. Benowitz N.L., and Jacob III P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56 (1994) 483-493
31. Benowitz N.L., and Jacob III P. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 53 (1993) 316-323
32. Kyvik K. Generalisability and assumptions of twin studies. In: Spector T., Snieder H., and MacGregor A. (Eds). Advances in twin and sib-pair analysis (2000), Greenwich Medical Media, London 67-77
33. Haberl M., Anwald B., Klein K., Weil R., Fuss C., Gepdiremen A., et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 15 (2005) 609-624
34. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M.A., Sakurai M., et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25 (2004) 2451-2458